AMSTERDAM, Sept. 7, 2018 /PRNewswire/ -- Elekta (EKTA-B.ST)
today announced that Elekta Unity, its transformative magnetic resonance radiation therapy (MR/RT) system, is now in clinical use
at The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL). Elekta Unity is the first system to combine
high-field (1.5 Tesla) MR imaging, precision radiation therapy and intelligent software, and is capable of MR/RT, a personalized
precision cancer therapy. Elekta Unity received CE mark in June 2018, and is being clinically
implemented in leading cancer centers throughout Europe.
"As a player on the international forefront of cancer care and research, we became a member of the Elekta MR-linac consortium
because we believed that real-time, high-field imaging during radiation delivery would transform cancer care and enable new
treatment regimens that offer patients improved safety and efficacy," said Marlies Nowee,
Radiation Oncologist, at NKI-AvL. "Elekta Unity is now a reality, and we are excited to start treating our patients. The ability
to see what we treat in real time and adapt treatment on a daily basis enables unprecedented precision and ensures that each
patient receives the right dose, delivered to the right location, at every treatment session. We are proud to have played a role
in bringing Elekta Unity into clinical use."
NKI-AvL, which is a founding member of Elekta's MR-linac Consortium, recently started treating its first patient using Elekta
Unity. The patient is receiving treatment for prostate cancer. The Elekta MR-linac Consortium is a collaborative
industrial-academic partnership that Elekta founded with seven centers and our technology partner, Philips in 2012 to provide an
evidence-based introduction of the MR-linac to the medical community, and to support the advancement of the technology.
"The NKI-AvL team made critical contributions to developing the technological innovations that allow Elekta Unity to perform
as no other radiation delivery system can, and we are gratified to see their patients reaping the rewards of their efforts," said
Richard Hausmann, Elekta President and CEO. "NKI-AvL is the second
cancer center in Europe to offer MR/RT with Elekta Unity to their patients, and additional
centers will be clinically implementing this personalized, precision cancer therapy in the weeks and months ahead. The strong
enthusiasm for this technology within the radiation oncology community reflects its truly novel capabilities and ease with which
it can be incorporated into routine clinical workflows."
To learn more, visit elekta.com/Unity.
Elekta Unity is pending 510(k) pre-market clearance and not available for commercial distribution or sale in the
U.S.
For further information, please contact:
Oskar Bosson
Global EVP Corporate Communications and Investor Relations
Tel: +46-70-410-7180
e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri
Global Public Relations Manager
Tel: +1-770-670-2524
e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people
with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than
6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to
enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows.
Elekta employs 3,700 people around the world. Headquartered in Stockholm, Sweden, Elekta is
listed on NASDAQ Stockholm. www.elekta.com.
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/elekta/r/magnetic-resonance-radiation-therapy-with-elekta-unity-is-now-in-clinical-use-at-the-netherlands-can,c2610271
The following files are available for download: